UPDATE: RBC Capital Markets Downgrades Baxter International

In a report published Tuesday, RBC Capital Markets analyst Brandon Henry downgraded Baxter International (NYSE: BAX ) to Sector Perform from Outperform, keeping its $73.00 price target. According to the report, it is expected that longer-acting products are to be a "game changer" for the Hemophilia A space as ~64%